P323 Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial

W. Sandborn, Irving H. Fox(Takeda (United States)), Catherine Milch(Millennium Engineering and Integration (United States)), M. Rosario, B E Sands(Icahn School of Medicine at Mount Sinai), Serap Sankoh(Millennium Engineering and Integration (United States)), Paul Rutgeerts(KU Leuven)
Journal of Crohn s and Colitis
February 1, 2013
10.1016/s1873-9946(13)60344-x
Cited by 6

Related Papers

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
The safety of vedolizumab for ulcerative colitis and Crohn's disease
|Gut|2016|810
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714